Is Now a Good Time to Buy CRISPR Therapeutics?
CRISPR Therapeutics (NASDAQ: CRSP) may be a few months away from a transformation. The company itself isn't changing, but its financial picture may be about to do so. That's because by year-end, regulators will make a decision about what could become CRISPR's first commercialized product.
CRISPR and big biotech partner Vertex Pharmaceuticals submitted exa-cel, a gene editing candidate for blood disorders, to regulators in the U.S., Europe, and the U.K. And U.S. regulators expect to issue a decision on the candidate for one particular indication -- sickle cell disease -- in December. They aim to decide on exa-cel for beta thalassemia in March.
Meanwhile, CRISPR shares have soared more than 40% since the start of the year. Is now a good time to buy CRISPR -- or is all the good news priced in?
Source Fool.com
Vertex Pharmaceuticals Inc. Stock
With 54 Buy predictions and 2 Sell predictions Vertex Pharmaceuticals Inc. is one of the favorites of our community.
However, we have a potential of -4.03% for Vertex Pharmaceuticals Inc. as the target price of 440 € is below the current price of 458.5 €.
